The research team searched five major databases—PubMed, Embase, Scopus, Web of Science and the Cochrane Central Register—through November 2025, screening more than 2,400 records under PRISMA 2020 guidelines. From that effort, eight unique studies contributing ten distinct comparisons made the final synthesis. Five comparisons came from propensity score-matched observational cohorts, four from nonmatched cohorts, and one from randomized trial data, including prespecified analyses of the FLOW and SOUL trials. The researchers deliberately excluded studies that reported only composite major adverse cardiovascular events, or MACE, insisting instead on separate data for myocardial infarction and stroke—a decision that proved scientifically decisive.

That insistence matters because composite endpoints have long been a blind spot in cardiovascular outcomes research. Myocardial infarction is fundamentally a coronary atherothrombotic event, driven by plaque rupture and clot formation in the heart’s arteries, while stroke is a heterogeneous condition involving both cerebrovascular atherosclerosis and cardioembolic pathways. Pooling these biologically distinct events into a single MACE score can mask divergent treatment effects, much like averaging the temperatures of two different cities. By disaggregating the endpoints, the researchers could ask a sharper question: does dual therapy protect the coronary arteries and the cerebral circulation equally?

The answer, intriguingly, is no. For myocardial infarction, combination therapy was associated with a pooled hazard ratio of 0.79, meaning a 21 percent relative risk reduction compared with monotherapy overall. Yet when the investigators stratified by comparator, a telling pattern emerged: dual therapy significantly outperformed SGLT2 inhibitor monotherapy for MI prevention (hazard ratio 0.74), but showed no statistically significant advantage over GLP-1 receptor agonist monotherapy (hazard ratio 0.80, confidence interval 0.55 to 1.16). In other words, the coronary benefit appears to be carried almost entirely by the GLP-1 receptor agonist component of the combination.

This finding aligns closely with the biology established by landmark cardiovascular outcome trials. GLP-1 receptor agonists exert robust antiatherosclerotic and antiinflammatory effects—improving endothelial function, plaque stability, body weight and blood pressure—making them particularly well suited to preventing atherothrombotic coronary events. In the HARMONY Outcomes trial, for instance, the GLP-1 agonist albiglutide reduced MACE, and among the individual components only myocardial infarction showed a statistically significant reduction. SGLT2 inhibitors, by contrast, deliver their most profound and reproducible benefits in heart failure and kidney protection, with more modest effects on atherosclerotic events. Adding an SGLT2 inhibitor to a patient already on a GLP-1 agonist may therefore offer limited incremental defense against coronary ischemia, because the atherothrombotic pathways are already being substantially modulated.

Stroke told a different and arguably more exciting story. Combination therapy was associated with a 15 percent lower stroke risk overall (hazard ratio 0.85), and unlike the MI findings, this benefit outperformed both individual drug classes: a 27 percent reduction versus SGLT2 inhibitor monotherapy and a statistically significant 8 percent reduction versus GLP-1 receptor agonist monotherapy. The advantage was concentrated in ischemic stroke specifically, with a hazard ratio of 0.67. The researchers propose a dual-pathway synergy: while the GLP-1 agonist stabilizes the cerebrovascular wall against atherosclerosis, the SGLT2 inhibitor contributes hemodynamic offloading, blood pressure lowering and possible antiarrhythmic effects. Supporting this framework, prior mechanistic studies have shown that combining the two agents improves endothelial glycocalyx integrity, pulse wave velocity, central systolic blood pressure and left atrial strain—parameters directly relevant to cardioembolic stroke risk.

Perhaps the most clinically provocative result was the age interaction. The cerebrovascular benefit appeared dramatically stronger in adults aged 65 and older, who showed a remarkable 50 percent relative reduction in stroke risk (hazard ratio 0.50), an effect absent in younger cohorts. The authors note that older adults carry a higher baseline burden of arterial stiffness, chronic kidney disease and occult atrial arrhythmias—pathophysiological domains where combined vascular and cardiorenal risk reduction may yield the greatest absolute benefit. However, they caution that this age-related signal, though statistically significant, rests on a limited number of comparisons and could reflect chance.

The analysis was not without warning signs. Substantial heterogeneity characterized both endpoints, with I-squared values of 72.8 percent for MI and 63.5 percent for stroke. Sensitivity analyses revealed that nonmatched observational cohorts produced a larger MI association (hazard ratio 0.67) than propensity-matched comparisons (hazard ratio 0.87), a statistically significant difference that suggests residual confounding and treatment-selection bias may inflate the apparent benefit in less rigorous study designs. One exploratory subgroup even showed elevated stroke risk among baseline insulin users (hazard ratio 2.33), though this rested on a single comparison and may simply reflect confounding by indication, since insulin use often marks more advanced disease. Applying the GRADE framework, the researchers rated the overall certainty of evidence as very low for both endpoints.

The authors are emphatic that these findings are hypothesis-generating rather than practice-changing. Current American Diabetes Association guidelines already recommend tailoring therapy to individual cardiovascular risk profiles, and both drug classes are well established individually; the new analysis does not mandate dual therapy solely for MI or stroke prevention. Instead, the results suggest that when both agents are already clinically appropriate for a patient’s broader cardiometabolic needs—glycemic control, weight management, heart failure risk—the potential for vascular-specific protection adds a further rationale. Notably, the safety profile of the combination appears favorable, with adverse events remaining largely class-specific: genital mycotic infections and rare euglycemic ketoacidosis for SGLT2 inhibitors, gastrointestinal intolerance for GLP-1 agonists, and a need for careful insulin adjustment to avoid hypoglycemia.

What the field needs next, the researchers argue, are dedicated prospectively powered randomized trials designed from the outset to compare combination therapy against active monotherapy, powered for individual coronary and cerebrovascular events rather than composite MACE. Such trials should capture stroke subtypes, fatal versus nonfatal events, and the sequencing question of simultaneous initiation versus sequential add-on. Until then, this meta-analysis offers a compelling physiological preview: two blockbuster drug classes, each famous in its own right, may protect the heart and the brain through complementary, nonredundant mechanisms—and the patients who stand to gain the most from putting them together may be older adults at high cerebrovascular risk.

Subject of Research: The effect of combined SGLT2 inhibitor and GLP-1 receptor agonist therapy on myocardial infarction and stroke risk in adults with type 2 diabetes

Article Title: Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Article References: Ghafoury, R., Naghshbandi, M., Malek, M., Kalra, S., Ismail-Beigi, F., & Khamseh, M. E. (2026). Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01911-2

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01911-2

Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, myocardial infarction, stroke, combination therapy, meta-analysis, cardiovascular outcomes, Diabetes Therapy, ischemic stroke, cardiometabolic medicine, GRADE certainty